This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Novartis AG

Drug Names(s): rivastigmine tartrate, Prometax (EU), ENA 713

Description: Exelon (Rivastigmine tartrate) is a reversible cholinesterase inhibitor. Inhibition of cholinesterases, which break down acetylcholine, leads to increased levels of acetylcholine in the brain, helping to boost cognition in Alzheimer's disease, where acetylcholine containing nerves are reduced. Exelon is 4-6 times selective for the G1 (monomeric, intracellular) form of AChE rather than G4 (tetrameric, cell membrane-bound). It inhibits both acetylcholinesterase and butyrylcholinesterase in the CSF. However, these particular differences have not been shown to lead to meaningful advantages.

Deal Structure: Historical sales for Exelon include the sales from Exelon Patch.

Generic entries of Exelon have entered the market in Japan, Europe, and the United States. Exelon Patch also now has generic entry in the some European states and four generic manufacturers have filed applications to market generic versions of Exelon Patch in the US. Based on this information and a decrease from all Exleon/Exelon Patch revenue, BioMedTracker no longer forecasts revenues.

Exelon News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug